Thera-SAbDab

DARATUMUMAB

>   Structural Summary
TherapeuticDaratumumab
TargetADPRC1/CD38
Heavy ChainEVQLLESGGGLVQPGGSLRLSCAVSGFTFNSFAMSWVRQAPGKGLEWVSAISGSGGGTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYFCAKDKILWFGEPVFDYWGQGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPTFGQGTKVEIK
100% seqID Fv Structure7dha [Fvs: CB], 7dun [Fvs: HL], 7duo [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Approved
Estimated Status (Aug '24)Active
Recorded Developmental TechnologyMedarex HuMAb Mouse
INN Year Proposed2009
INN Year Recommended2010
Companies InvolvedBoston Medical Center, Bristol-Myers Squibb, Dana-Farber Cancer Institute, French Innovative Leukemia Organisation, Genentech, Genmab, Janssen Biotech, Janssen Research & Development, M. D. Anderson Cancer Center, Syros Pharmaceuticals
Conditions ApprovedMultiple myeloma
Conditions ActiveAmyloid light-chain amyloidosis, Acute myeloid leukaemia, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Mantle-cell lymphoma, Myelodysplastic syndromes, Precursor B-cell lymphoblastic leukaemia-lymphoma, Precursor T-cell lymphoblastic leukaemia-lymphoma, Prostate cancer, T-cell lymphoma, Waldenstrom's macroglobulinaemia, Solid tumours
Conditions DiscontinuedNon-small cell lung cancer
Notes

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy